Literature DB >> 23532573

Urokinase plasminogen activator receptor: a functional integrator of extracellular proteolysis, cell adhesion, and signal transduction.

Gian Maria Sarra Ferraris1, Nicolai Sidenius.   

Abstract

The urokinase plasminogen activator receptor (uPAR) is a cell surface receptor involved in a multitude of physiologic and pathologic processes. uPAR regulates simultaneously a branch of the plasminogen activator system and modulates cell adhesion and intracellular signaling by interacting with extracellular matrix components and signaling receptors. The multiple uPAR functions are deeply interconnected, and their integration determines the effects that uPAR expression triggers in different contexts. The proteolytic function of uPAR affects both the signaling and the adhesive functions of the receptor, whereas these latter two are closely interconnected. This review focuses on the molecular mechanisms that connect and mutually regulate the different uPAR functions. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23532573     DOI: 10.1055/s-0033-1334485

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  14 in total

1.  Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.

Authors:  Kasper Almholt; Ole Didrik Lærum; Boye Schnack Nielsen; Ida Katrine Lund; Leif Røge Lund; John Rømer; Annika Jögi
Journal:  Clin Exp Metastasis       Date:  2015-06-04       Impact factor: 5.150

2.  Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.

Authors:  Valentina De Lorenzi; Gian Maria Sarra Ferraris; Jeppe B Madsen; Michela Lupia; Peter A Andreasen; Nicolai Sidenius
Journal:  EMBO Rep       Date:  2016-05-17       Impact factor: 8.807

3.  uPAR promotes tumor-like biologic behaviors of fibroblast-like synoviocytes through PI3K/Akt signaling pathway in patients with rheumatoid arthritis.

Authors:  Yan Liu; Yun Feng Pan; You-Qiu Xue; Lin-Kai Fang; Xing-Hua Guo; Xin Guo; Meng Liu; Bi-Yao Mo; Meng-Ru Yang; Fang Liu; Yun-Ting Wu; Nancy Olsen; Song Guo Zheng
Journal:  Cell Mol Immunol       Date:  2017-01-16       Impact factor: 11.530

4.  Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Black Adults.

Authors:  Nels C Olson; Laura M Raffield; Anne H Moxley; Tyne W Miller-Fleming; Paul L Auer; Nora Franceschini; Debby Ngo; Timothy A Thornton; Ethan M Lange; Yun Li; Deborah A Nickerson; Neil A Zakai; Robert E Gerszten; Nancy J Cox; Adolfo Correa; Karen L Mohlke; Alexander P Reiner
Journal:  Circ Genom Precis Med       Date:  2021-10-28

Review 5.  uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.

Authors:  Michael J Duffy; Patricia M McGowan; Nadia Harbeck; Christoph Thomssen; Manfred Schmitt
Journal:  Breast Cancer Res       Date:  2014-08-22       Impact factor: 6.466

6.  Urokinase-type plasminogen activator: a new target for male contraception?

Authors:  Ying Qin; Yan Han; Cheng-Liang Xiong; Hong-Gang Li; Lian Hu; Ling Zhang
Journal:  Asian J Androl       Date:  2015 Mar-Apr       Impact factor: 3.285

Review 7.  Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins.

Authors:  Martin C Boonstra; Susanna W L de Geus; Hendrica A J M Prevoo; Lukas J A C Hawinkels; Cornelis J H van de Velde; Peter J K Kuppen; Alexander L Vahrmeijer; Cornelis F M Sier
Journal:  Biomark Cancer       Date:  2016-09-27

8.  Serum levels of urokinase-type plasminogen activator in healthy dogs and oncologic canine patients.

Authors:  Sofia C Ramos; Augusto J de Matos; João Niza Ribeiro; Liliana R Leite-Martins; Rui R F Ferreira; Inês Viegas; Andreia A Santos
Journal:  Vet World       Date:  2017-08-14

Review 9.  Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine.

Authors:  Adel Gouri; Aoulia Dekaken; Khalid El Bairi; Arifa Aissaoui; Nihad Laabed; Mohamed Chefrour; Joseph Ciccolini; Gérard Milano; Sadek Benharkat
Journal:  Biomark Insights       Date:  2016-08-16

10.  Overexpression of forkhead box M1 and urokinase-type plasminogen activator in gastric cancer is associated with cancer progression and poor prognosis.

Authors:  Jie Ma; Guangwei Qi; Ji Xu; Haibing Ni; Wulin Xu; Guoqing Ru; Zhongsheng Zhao; Wenjuan Xu; Xujun He
Journal:  Oncol Lett       Date:  2017-10-04       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.